Pathogen Inactivated Blood Components: Advancing from Theory to Practice

  • M. Conlan
  • L. Corash
  • D. Ramies
  • David S. Wages
Part of the Developments in Hematology and Immunology book series (DIHI, volume 37)


Although the safety of the blood supply has been dramatically improved over the past two decades, allogeneic blood components still carry infectious risks. This is in marked contrast to other therapeutic compounds such as small molecules or even recombinant biologics such as insulin or growth factors. Currently, prevention of transfusion-associated disease depends on a pre-donation interview of potential donors followed by laboratory testing of the donor’s blood for infectious pathogens prior to release of the donor’s blood. Serologic testing is performed to detect retroviruses such as the Human Immunodeficiency Virus (HIV) as well as a number of the hepatitis viruses such as hepatitis B. Serologic screening is not routinely done for parvo virus B 19, hepatitis A, E and G. Further, with one exception, no screening tests for bacteria or protozoa exist. Recently, the scope and sensitivity of donor screening for viral infection has expanded by the addition of specific nucleic acid amplification tests. The addition of these screening tests has greatly narrowed the “window period” in which a seronegative donor might still transmit a viral infection.


Fresh Freeze Plasma Baxter Healthcare Donor Screening Count Increment Fresh Freeze Plasma Transfusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP, Transfusion Medicine: First of Two Parts; N Engl J Med 1999; 340: 438–47.Google Scholar
  2. 2.
    Ling AE, Robbins ICE, Brown TM et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000; 284: 238–40.CrossRefGoogle Scholar
  3. 3.
    Schuttler GC, Caspari C, Jursch CA, Gerlich WH, Schafer S. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000; 355: 41–42.PubMedCrossRefGoogle Scholar
  4. 4.
    McDonald CP, Hartley S, Orchard K, et al. Fatal Clostridium perfringens sepsis from a pooled platelet transfusion. Transfusion Med 1998; 8: 19–22.CrossRefGoogle Scholar
  5. 5.
    Chiu EKW, Yuen KY, Lie AKW et al. A prospective study of symptomatic bacteremia following platelet transfusion and its management. Transfusion 1994; 34: 950–54.PubMedCrossRefGoogle Scholar
  6. 6.
    AuBuchon JP, Birkmeyer JD, Busch M. Safety of the blood supply in the United States: opportunities and controversies. Ann Int Med 1997; 127: 90509.Google Scholar
  7. 7.
    Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Corten L, Wiesehahn GP, Smyers JM et al. Photochemical inactivation of hepatitis B (HBV) and Hepatitis C (HCV) viruses in human plasma as assessed in a chimpanzee infectivity model. Blood 2000;96:Supplement 1.Google Scholar
  9. 9.
    Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 314047.Google Scholar
  10. 10.
    Gmur J, Burger J, Schanz U, Fehr, Schaffner A. Safety of a stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991; 338: 1223–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Weiskopf, R. Do we know when to transfuse red cells to treat acute anemia? Transfusion. 1998; 38: 517–21.PubMedCrossRefGoogle Scholar
  12. 12.
    deAlarcon P, Benjamin R, Shopnick M et al. An open-label trial of Fresh Frozen Plasma (FIT) treated by the HelinxTM single-unit photochemical pathogen inactivation system in patients with congenital coagulation factor deficiencies. Blood 2000;96 supplement 1: 254.Google Scholar
  13. 13.
    Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coag Fibrinolysis. 1993; 4: 599–604.CrossRefGoogle Scholar
  14. 14.
    Moroff G, Sohmer PR, Button LN et al. Proposed standardization of methods for determining the 24-hour survival of stored red cells. Trans-fusion 1984; 24: 109–14.Google Scholar
  15. 15.
    Heaton, WAL. Evaluation of posttransfusion recovery and survival of transfused red cells. Transfusion Med Reviews 1992; 6: 153–69.CrossRefGoogle Scholar
  16. 16.
    Lotter G, Rabe W, de Lange A, et al. Reference values for red cell survival times. J Nucl Med 1991; 32: 2245–48.PubMedGoogle Scholar
  17. 17.
    Rios J, Hambleton J, Viele M, et al. HelinxTM treated RBC transfusions are well tolerated and show comparable recovery and survival to control RBCs. Transfusion. 2001;41:supplement 38s.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • M. Conlan
  • L. Corash
  • D. Ramies
  • David S. Wages
    • 1
  1. 1.Medical AffairsCerus CorporationConcordUSA

Personalised recommendations